TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06640634

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)
Description: Sham in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. In the sham tDCS groups, the duration and electrodes application were the same of active in therapeutic tDCS (Th-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)
Description: Active in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)
Description: Sham in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. In the sham tDCS groups, the duration and electrodes application were the same of active in preventive tDCS (Pr-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
Study: NCT06599320

Intervention type: OTHER
Intervention: Oral rehabilitation with dental implants
Description: Patients rehabilitated with implant-supported fixed partial dental prostheses
Study: NCT05336357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy
Description: Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 65 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell.
Study: NCT05200364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: intravenous antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: anti-VEGF agent
Study: NCT05355298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP945 ascending doses
Description: Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP945 RP2D
Description: Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
Study: NCT06662513

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No intervention - retrospective observational study
Study: NCT05846451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Immediate-release oral tablet, 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Immediate-release oral tablet, 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Immediate-release oral tablet, 10 mg
Study: NCT05257837

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gun handling behavior
Description: Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gun handling behavior
Description: Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gun handling behavior
Description: Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger
Study: NCT06658067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.
Study: NCT06172465

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EOIP
Description: Ultrasound guided External oblique intercostal block will be performed bilaterally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OSTAP
Description: Ultrasound guided oblique subcostal transversus abdominis plane block will be performed bilaterally.
Study: NCT06637332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin for Injection
Description: Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
Study: NCT06606275

Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, playing a crucial role in preventing blood clot formation. It is commonly prescribed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and for treating and preventing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin is a vitamin K antagonist widely used as an anticoagulant to prevent thromboembolic events, particularly in conditions like atrial fibrillation, venous thromboembolism, and in patients with mechanical heart valves. It inhibits the enzyme vitamin K epoxide reductase, thereby reducing the activation of vitamin K-dependent clotting factors (II, VII, IX, X) and regulatory proteins C and S. Due to its narrow therapeutic index, warfarin requires regular monitoring of the International Normalized Ratio (INR) to optimize anticoagulation while minimizing the risk of bleeding. Warfarin's pharmacokinetics and pharmacodynamics can be influenced by genetic polymorphisms, diet, and drug interactions, necessitating individualized dosing strategies.
Study: NCT06670677

Intervention type: OTHER
Intervention: Lifestyle survey completion
Description: For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.

Intervention type: OTHER
Intervention: Lifestyle survey completion
Description: For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.

Intervention type: OTHER
Intervention: Lifestyle survey completion
Description: For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.

Intervention type: OTHER
Intervention: Unlimited on-demand blood pressure measurements with G2C
Description: For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated

Intervention type: OTHER
Intervention: Unlimited on-demand blood pressure measurements with G2C
Description: For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated

Intervention type: OTHER
Intervention: Unlimited on-demand blood pressure measurements with G2C
Description: For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated
Study: NCT06637332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (IV)
Description: Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
Study: NCT04913220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion
Study: NCT06670677

Intervention type: OTHER
Intervention: Continual blood pressure measurements with G1
Description: For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.

Intervention type: OTHER
Intervention: Continual blood pressure measurements with G1
Description: For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.
Study: NCT05145816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 2.5 mg/kg (8 weeks)
Description: 2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
Study: NCT04913220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Solution for infusion: intravenous infusion
Study: NCT05145816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 1.9 mg/kg (8 weeks)
Description: 1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 1.4 mg/kg (12 weeks)
Description: 1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Study: NCT06175234

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation Treatment
Description: For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter. For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.
Study: NCT06437353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily.
Study: NCT05145816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 1.9 mg/kg (12 weeks)
Description: 1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages
Description: Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 1.0 mg/kg (12 weeks)
Description: 1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Study: NCT05766280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCareer Soft Skills Training for Employment
Description: The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
Study: NCT06673641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CABTREO Topical Gel
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
Study: NCT06675786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I.V. House UltraDressing
Description: I.V. House UltraDressing (I.V. House, Inc., St. Louis, MO, USA) will be applied according to the manufacturer's instructions and secured with an anti-slip tape without the need for further taping. It is intended to prevent complications such as catheter-related displacement, phlebitis, infiltration, extravasation, catheter occlusion, and folding of PVCs.
Study: NCT06673940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: TENS is applied on the acupuncture points Intervention arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy program
Description: Physical therapy methods

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy program
Description: Physical therapy methods
Study: NCT06673914

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Diet Group
Description: Patient in Diet Group and Oleuropein and Diet Group will be given a personalized diet and be followed up by a dietician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group: Diet Group
Description: Patient in Diet Group and Oleuropein and Diet Group will be given a personalized diet and be followed up by a dietician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleuropein and Diet Group
Description: Dietary Supplement: Oleuropein (Olive Leaf Extract) Patients in Oleuropein and Diet Group will receive 200 mg/day oleuropein supplement and personalized diet followed up by a dietician.
Study: NCT06508944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal 17 beta-estradiol
Description: * Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks.
Study: NCT06673836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DYNAMIC CYCLING
Description: Balance Training: Exercises focused on improving coordination and balance, such as standing on one leg, walking on uneven surfaces, or using balance boards.~Core Strengthening: Strengthening core muscles helps children maintain stability during dynamic movements, such as walking or running.~Proprioceptive Training: Exercises that improve awareness of the body's position in space, such as obstacle courses or activities that challenge movement coordination.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INCLINED TREAD MILL
Description: Dynamic Cycling: Refers to the fluctuating nature of movement patterns, often used in therapies like stationary biking or recumbe.nt cycling, where the intensity and resistance vary. Dynamic cycling can also refer to training that involves alternating between high and low-intensity phases or cycling between different positions (sitting, standing) or speeds during the activity
Study: NCT06675409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The effectiveness of two different training methods with virtual patients for improving the critical decision-making skills of paramedic students will be compared between two groups: one receiving expert-guided training and the other following a self-directed approach
Study: NCT06508944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral modifications
Description: Behavioral modifications for women with storage symptoms of lower urinary tract symptoms (LUTS) involve strategies such as regulating fluid intake, avoiding bladder irritants, practicing bladder training techniques (scheduled and delayed voiding), performing pelvic floor muscle exercises, managing weight, increasing dietary fiber, maintaining a bladder diary, setting a regular voiding schedule, utilizing stress management techniques, and educating patients about LUTS.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral modifications
Description: Behavioral modifications for women with storage symptoms of lower urinary tract symptoms (LUTS) involve strategies such as regulating fluid intake, avoiding bladder irritants, practicing bladder training techniques (scheduled and delayed voiding), performing pelvic floor muscle exercises, managing weight, increasing dietary fiber, maintaining a bladder diary, setting a regular voiding schedule, utilizing stress management techniques, and educating patients about LUTS.
Study: NCT06028347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sa-mRNA vaccine Dose 1
Description: self-amplifying mRNA vaccine
Study: NCT06675409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The effectiveness of two different training methods with virtual patients for improving the critical decision-making skills of paramedic students will be compared between two groups: one receiving expert-guided training and the other following a self-directed approach
Study: NCT06674265

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogenic NK cells infusion
Description: Natural Killer (NK) cells are extracted from a healthy donor through apheresis and processed in a clean room using the CLINIMACS device. After quality assessment, these cells are stored at -198°C until needed. When required, the cells are thawed, washed, and evaluated for viability and sterility before being administered to the patient at a dosage of 5 × 10\^6 cells per kilogram of body weight. Two further injections may be considered based on the patient's response and confirmed improvement via MRI MIBG. Injections are scheduled seven to ten days after each chemotherapy course according to the standard treatment protocol.
Study: NCT06609304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Axicabtagene Ciloleucel at 2.0×10\^6/Kg